You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 27, 2024

VIDEX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Videx, and when can generic versions of Videx launch?

Videx is a drug marketed by Bristol and Bristol Myers Squibb and is included in four NDAs.

The generic ingredient in VIDEX is didanosine. There are eight drug master file entries for this compound. Additional details are available on the didanosine profile page.

Paragraph IV (Patent) Challenges for VIDEX
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VIDEX Capsules didanosine 75 mg 020155 1 2011-06-06

US Patents and Regulatory Information for VIDEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol VIDEX didanosine FOR SOLUTION;ORAL 020156-001 Oct 9, 1991 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bristol Myers Squibb VIDEX didanosine TABLET, CHEWABLE;ORAL 020154-003 Oct 9, 1991 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bristol Myers Squibb VIDEX didanosine FOR SOLUTION;ORAL 020155-005 Oct 9, 1991 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bristol Myers Squibb VIDEX EC didanosine CAPSULE, DELAYED REL PELLETS;ORAL 021183-002 Oct 31, 2000 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bristol Myers Squibb VIDEX didanosine TABLET, CHEWABLE;ORAL 020154-004 Oct 9, 1991 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VIDEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb VIDEX didanosine TABLET, CHEWABLE;ORAL 020154-004 Oct 9, 1991 ⤷  Sign Up ⤷  Sign Up
Bristol Myers Squibb VIDEX didanosine TABLET, CHEWABLE;ORAL 020154-005 Oct 9, 1991 ⤷  Sign Up ⤷  Sign Up
Bristol Myers Squibb VIDEX didanosine TABLET, CHEWABLE;ORAL 020154-003 Oct 9, 1991 ⤷  Sign Up ⤷  Sign Up
Bristol Myers Squibb VIDEX didanosine FOR SOLUTION;ORAL 020155-005 Oct 9, 1991 ⤷  Sign Up ⤷  Sign Up
Bristol VIDEX didanosine FOR SOLUTION;ORAL 020156-001 Oct 9, 1991 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for VIDEX

See the table below for patents covering VIDEX around the world.

Country Patent Number Title Estimated Expiration
Canada 2074215 FORMULATIONS ORALES AMELIOREES DE NUCLEOSIDES A BASE DE DIDEOXYPURINE (IMPROVED ORAL DOSING FORMULATIONS OF DIDEOXY PURINE NUCLEOSIDES) ⤷  Sign Up
Greece 3026332 ⤷  Sign Up
Finland 105153 ⤷  Sign Up
Hong Kong 47694 Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine, or 2'3'-dideoxyadenosine ⤷  Sign Up
Germany 69224684 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VIDEX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0216510 94C0006 Belgium ⤷  Sign Up PRODUCT NAME: DIDANOSINE; NAT. REG.: 203 IS 225 F 3 19930331; FIRST REG.: FR 557 386-4 19920505
0216510 SZ 54/1994 Austria ⤷  Sign Up PRODUCT NAME: 2',3'-DIDEOXYINOSIN
0285237 94C0006 France ⤷  Sign Up PRODUCT NAME: DIDANOSINE; NAT. REG.: 203 IS 225 F 3 19930331; FIRST REG.: FR 557 386-4 19920505
0216510 SPC/GB94/005 United Kingdom ⤷  Sign Up SPC/GB94/005:, EXPIRES: 20070504
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.